To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

Phase 2CompletedNCT00991419

AstraZeneca25 enrolled

Overview

The purpose of this study is to compare PET measurements of fibrillar amyloid burden using \[18F\]AZD4694.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Alzheimer's Disease

Interventions

[18F]AZD4694DRUG

\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, of any race or/ethnicity * ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician Exclusion Criteria: * Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse * Participated in a PET study within the last 12 months * Pregnancy or lactation

Locations (1)

Research Site

Phoenix, Arizona, United States

Outcomes

Primary Outcomes

PET Measurements

Time frame: Day 1 and Day 7

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.